Spruce Biosciences, Inc.
SPRB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $697 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $697 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $5,011 | $0 | $10,837 | $21,457 |
| G&A Expenses | $3,218 | $3,122 | $3,655 | $3,314 |
| SG&A Expenses | $3,218 | $3,122 | $3,655 | $3,314 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$430 | $0 | $0 |
| Operating Expenses | $8,229 | $2,692 | $14,492 | $24,771 |
| Operating Income | -$8,229 | -$2,692 | -$14,492 | -$24,074 |
| % Margin | – | – | – | -3,453.9% |
| Other Income/Exp. Net | $17 | $625 | $451 | $515 |
| Pre-Tax Income | -$8,212 | -$2,067 | -$14,041 | -$23,559 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,212 | -$2,067 | -$14,041 | -$23,559 |
| % Margin | – | – | – | -3,380.1% |
| EPS | -14.58 | -3.41 | -24 | -43.5 |
| % Growth | -327.6% | 85.8% | 44.8% | – |
| EPS Diluted | -14.58 | -3.41 | -24 | -43.5 |
| Weighted Avg Shares Out | 563 | 606 | 571 | 536 |
| Weighted Avg Shares Out Dil | 563 | 606 | 571 | 536 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $654 | $487 | $571 |
| Interest Expense | $19 | $29 | $36 | $56 |
| Depreciation & Amortization | $3 | $7 | $6 | $9 |
| EBITDA | -$8,190 | -$2,031 | -$13,999 | -$23,494 |
| % Margin | – | – | – | -3,370.7% |